PAREXEL AND SALEM STATE UNIVERSITY LAUNCH CLINICAL TRIAL MANAGEMENT GRADUATE PROGRAM
Public-private partnership created to help educate and develop the future biopharmaceutical workforce
Boston, MA., September 20, 2012 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced a partnership with Salem State University to offer a Post Graduate Certificate Program in Clinical Trial Management. This collaboration will provide candidates with the education needed to succeed in the growing clinical research management industry.
PAREXEL is committed to developing the future biopharmaceutical workforce with courses specifically tailored to meet the growing talent needs of the clinical development job market. Salem State University is an ideal partner to help further this effort due to its experience in developing academic programs relevant to workforce needs in the healthcare and life science fields.
“Salem State has a progressive outlook in partnering with industries and an impressive track record in building career interest in science disciplines,” said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International. “PAREXEL has experienced rapid growth in the United States and we are excited to have a major university partner in the Northeast to further develop the much-needed talent pool of candidates in the field.”
“Our partnership with PAREXEL International is a strong example of Salem State’s commitment to working with industry to create workforce aligned programs,” said Patricia Maguire Meservey, president of Salem State University. “There is a clear need here for people with a healthcare or life sciences background who, with the right training, can tap into a specialized area where there is great demand.”
PAREXEL has a well-established history of developing close partnerships with regional universities through its PAREXEL Academy. The company established the first academy of its kind in Berlin, Germany in 2001, where candidates can earn a Bachelor of Science (BSc) in Clinical Research degree validated and awarded by the University of Wales. More recently, PAREXEL entered into an agreement with the National University of Singapore (NUS), through its National University of Singapore Academy of GxP Excellence (NUSAGE), to offer an academic program to help meet the increasing demand for talent in the field of clinical research in the Asia region. Since its inception, PAREXEL International has helped train more than one thousand professionals and has successfully placed many of its graduates into the life sciences industry segment.
About Salem State University
Salem State University, established in 1854, is a comprehensive, public institution of higher learning located approximately 15 miles north of Boston, Massachusetts. The university enrolls over 10,000 undergraduate and graduate students representing 27 states and 57 nations, and is one of the largest state universities in the Commonwealth of Massachusetts.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 51 countries around the world, and has approximately 12,695 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2012 as filed with the SEC on August 27, 2012, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark and PAREXEL MyTrials is a trademark of PAREXEL International Corporation and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.